Evidence map›Paper›PMID 41029389›Full record

ArticleJournal of animal science and biotechnology2025

Effects of dietary L-glutamate and L-aspartate supplementation on growth performance, severity of diarrhea, intestinal barrier integrity, and fecal microbiota of weaned piglets challenged with F18 enterotoxigenic Escherichia coli.

Supatirada Wongchanla, Kunal Dixit, Sangwoo Park, Kwangwook Kim, Shuhan Sun, Maria Marco, Steven B Palomares, Alejandra Mejia-Caballero, Sahana Mohan, Xunde Li and 2 more

Abstract read
In one paragraph

Article in Journal of animal science and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Supatirada WongchanlaDepartment of Animal Science, University of California, Davis, USA.
Kunal DixitDepartment of Food Science and Technology, University of California, Davis, USA.
Sangwoo ParkDepartment of Animal Science, University of California, Davis, USA.
Kwangwook KimDepartment of Animal Science, Michigan State University, East Lansing, USA.
Shuhan SunDepartment of Animal Science, University of California, Davis, USA.
Maria MarcoDepartment of Food Science and Technology, University of California, Davis, USA.
Steven B PalomaresDepartment of Food Science and Technology, University of California, Davis, USA.
Alejandra Mejia-CaballeroDepartment of Food Science and Technology, University of California, Davis, USA.
Sahana MohanDepartment of Food Science and Technology, University of California, Davis, USA.
Xunde LiDepartment of Population Health & Reproduction, University of California, Davis, USA.
Xiaojing LiUnited Animal Health, Sheridan, IN, USA.
Yanhong LiuDepartment of Animal Science, University of California, Davis, USA. yahliu@ucdavis.edu.ORCID http://orcid.org/0000-0001-7727-4796

Funding

Novo Nordisk Fonden NNFSA210073688
6 · The paper itself

Abstract

backgroundL-Glutamate and L-aspartate are functional amino acids that play pivotal roles in the cellular metabolic pathways of swine enterocytes. Therefore, this study aimed to investigate the effects of dietary L-glutamate and L-aspartate on growth performance, diarrhea severity, intestinal barrier integrity, and fecal microbiota of weaned piglets challenged with F18 enterotoxigenic Escherichia coli (ETEC). Weaned piglets were randomly assigned to seven dietary treatments, including unchallenged and ETEC-challenged controls, amino acid-supplemented groups, and an antibiotic control, to assess their responses to ETEC challenge.

resultsSupplementation with 1% L-glutamate or 2% L-aspartate enhanced growth performance, with significantly greater (P < 0.05) average daily weight gain and gain-to-feed ratio compared with the positive control group from d 0 to d 5 post-inoculation. Pigs fed with 1% or 2% L-aspartate had reduced (P < 0.05) diarrhea severity in ETEC-challenged pigs compared with the positive control group. The 1% L-aspartate supplementation also supported intestinal structure by increasing (P < 0.05) duodenal villi height and ileal villi width compared with carbadox supplementation. Additionally, 1% L-glutamate supplementation significantly improved (P < 0.05) resilience in ETEC-challenged pigs by reducing fecal shedding of β-hemolysin-producing bacteria compared with the positive control group on d 14 post-inoculation. Moreover, 1% L-aspartate supplementation promoted intestinal barrier integrity by significantly up-regulated (P < 0.05) the expression of ileal OCDN and ileal ZO-1 compared with the positive control group on d 14 post-inoculation. Interestingly, 2% L-aspartate supplementation altered the intestinal mucosa by down-regulating (P < 0.05) the expression of jejunal CLDN-1, while up-regulating (P < 0.05) the expression of ileal CLDN-1 compared with the negative control group on d 14 post-inoculation. Furthermore, L-glutamate supplementation significantly changed proportions of Firmicutes and Bacteroidota and showed the trend for enrichment in beneficial bacterial genera such as Bifidobacterium and Megasphaera in ETEC-infected pigs by d 14 post-inoculation.

conclusionSupplementation with L-glutamate or L-aspartate promoted growth performance, supported gut health, and enhanced disease resistance in weaned pigs challenged with F18 ETEC. During the weaning period, L-glutamate or L-aspartate could potentially be considered conditionally essential amino acids, helping to alleviate weaning complications and reduce the need for antibiotic use in swine farming.

Indexed as

DiarrheaEscherichia coliFecal microbiotaL-AspartateL-GlutamateWeaned pigs

Identifiers

PMID41029389
PMCPMC12482100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.